Head and Neck Cancer News and Research RSS Feed - Head and Neck Cancer News and Research

Head and Neck Cancer is cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx [voice box]).
Oral afatinib significantly improves progression-free survival in patients with head and neck cancer

Oral afatinib significantly improves progression-free survival in patients with head and neck cancer

The tyrosine kinase inhibitor afatinib significantly improved progression-free survival compared to methotrexate in patients with recurrent or metastatic squamous cell carcinoma of the head and neck after failure of platinum-based chemotherapy, the results of a phase III trial show. [More]
Feist-Weiller, Caris Life Sciences partner to offer breakthrough technology to cancer patients

Feist-Weiller, Caris Life Sciences partner to offer breakthrough technology to cancer patients

Doctors at the LSU Health Shreveport Feist-Weiller Cancer Center will now have access to innovative, precision-medicine technology that determines the unique biological characteristics of each individual patient's cancer tumor. [More]
Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended June 30, 2014. Total revenue was $3.8 million and $6.2 million for the three and six months ended June 30, 2014, compared to $786,000 and $2.2 million for the same periods in 2013. [More]
Oncolytics Biotech announces financial results and operational highlights for second quarter 2014

Oncolytics Biotech announces financial results and operational highlights for second quarter 2014

Oncolytics Biotech Inc. today announced its financial results and operational highlights for the second quarter ended June 30, 2014. [More]
Biomarker for head and neck cancers identified

Biomarker for head and neck cancers identified

Although mutations in a gene dubbed "the guardian of the genome" are widely recognized as being associated with more aggressive forms of cancer, researchers at the University of California, San Diego School of Medicine have found evidence suggesting that the deleterious health effects of the mutated gene may in large part be due to other genetic abnormalities, at least in squamous cell head and neck cancers. [More]
Diabetes linked to increased head and neck cancer risk

Diabetes linked to increased head and neck cancer risk

People with diabetes mellitus have a significantly increased risk of developing head and neck cancer compared with those without the condition, show results of a large study conducted in Taiwan. [More]
TRIP13 protein encourages cancer cells to repair themselves

TRIP13 protein encourages cancer cells to repair themselves

Imagine you're fighting for your life but no matter how hard you hit, your opponent won't go down. The same can be said of highly treatment-resistant cancers, such as head and neck cancer, where during radiation and chemotherapy some cancer cells repair themselves, survive and thrive. [More]
Montefiore-Einstein investigators to present new findings from eight abstracts at IFHNOS 2014

Montefiore-Einstein investigators to present new findings from eight abstracts at IFHNOS 2014

Clinicians and researchers from Montefiore Medical Center and the Albert Einstein College of Medicine of Yeshiva University will present new findings from eight abstracts at the International Federation of Head and Neck Oncologic Societies World Congress being held July 26 - July 30 in New York. [More]
Advaxis, MedImmune team up for immuno-oncology clinical trial

Advaxis, MedImmune team up for immuno-oncology clinical trial

Advaxis, Inc., a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca. [More]
Researchers find way to diagnose aggressiveness of oral cancer

Researchers find way to diagnose aggressiveness of oral cancer

Studying mouth cancer in mice, researchers have found a way to predict the aggressiveness of similar tumors in people, an early step toward a diagnostic test that could guide treatment, according to researchers at Washington University School of Medicine in St. Louis. [More]
New tool could help predict patient's risk for financial toxicity

New tool could help predict patient's risk for financial toxicity

Cancer care has a new side effect. Along with the distress that comes with a cancer diagnosis and the discomforts of treatment, more patients now have to deal with "financial toxicity," the expense, anxiety and loss of confidence confronting those who face large, unpredictable costs, often compounded by decreased ability to work. [More]
FDA approves use for Lymphoseek to help doctors determine extent of neck and cancer

FDA approves use for Lymphoseek to help doctors determine extent of neck and cancer

The U.S. Food and Drug Administration today approved a new use for Lymphoseek (technetium 99m tilmanocept) Injection, a radioactive diagnostic imaging agent used to help doctors determine the extent a type of cancer called squamous cell carcinoma has spread in the body's head and neck region. [More]
Inovio evaluates responses of immunotherapy product in treating HPV linked head and neck cancer

Inovio evaluates responses of immunotherapy product in treating HPV linked head and neck cancer

Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced it has initiated a phase I/IIa clinical trial to evaluate safety, immunogenicity and clinical responses of its immunotherapy product, INO-3112, in treating human papillomavirus (HPV)- associated head and neck cancer. [More]
Survival rates for African-Americans with head and neck cancer not improved in the last 40 years

Survival rates for African-Americans with head and neck cancer not improved in the last 40 years

The national survival rates for African-Americans diagnosed with head and neck cancer have not improved in the last 40 years despite advances in the treatment and management of the disease, University of Missouri School of Medicine researchers have found in a new study. [More]
Study suggests proton therapy may be effective, less toxic treatment option for head and neck cancer

Study suggests proton therapy may be effective, less toxic treatment option for head and neck cancer

In a small study, researchers from The University of Texas MD Anderson Cancer Center found that 93 percent of head and neck cancer patients treated with multi-field optimization intensity modulated proton therapy (MFO-IMPT) were cancer-free 28 months after treatment. [More]
Bristol-Myers Squibb announces study results of nivolumab drug in patients with renal cell carcinoma

Bristol-Myers Squibb announces study results of nivolumab drug in patients with renal cell carcinoma

Bristol-Myers Squibb Company today announced results from a Phase 2 and a Phase 1b study of its investigational PD-1 immune checkpoint inhibitor nivolumab in patients with advanced or metastatic renal cell carcinoma (RCC), commonly known as kidney cancer. [More]
Bristol-Myers Squibb reports updated survival data from Phase 1b study of advanced melanoma

Bristol-Myers Squibb reports updated survival data from Phase 1b study of advanced melanoma

Bristol-Myers Squibb Company today announced updated survival data from the advanced melanoma cohort of Phase 1b study. [More]
Inovio Pharmaceuticals reports total revenue of $2.4 million for first quarter 2014

Inovio Pharmaceuticals reports total revenue of $2.4 million for first quarter 2014

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2014. [More]

ArQule reports net loss of $7,141,000 in first quarter 2014

ArQule, Inc. today announced its financial results for the first quarter of 2014. For the quarter ended March 31, 2014, the Company reported a net loss of $7,141,000 or $0.11 per share, compared to a net loss of $5,775,000, or $0.09 per share, for the first quarter of 2013. [More]
RTOG 9003: Hyperfractionated RT improves overall survival in patients with head and neck cancer

RTOG 9003: Hyperfractionated RT improves overall survival in patients with head and neck cancer

Patients with locally advanced squamous cell carcinoma of the head and neck treated with hyperfractionated radiation therapy (HFX) experienced improved local-regional control and, with patients censored at five years, improved overall survival with no increase in late toxicity, according to a study published in the May 1, 2014 edition of the International Journal of Radiation Oncology ● Biology ● Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO). [More]